>Marché des vecteurs lentiviraux en Asie-Pacifique, par composant (promoteur lentiviral, étiquettes de fusion lentivirales, systèmes d'emballage lentiviraux, autres), type (produit, services), génération (4e génération, 3e génération, 2e génération, 1re génération), flux de travail (traitement en amont, traitement en aval), méthode d'administration (in vivo, ex vivo), indication de maladie (cancer, troubles génétiques, maladies infectieuses , maladie vétérinaire, autre), application (thérapie génique, vaccinologie), utilisateur final (sociétés de biotechnologie, sociétés pharmaceutiques, organisations de recherche sous contrat, organisation de développement et de fabrication sous contrat (CDMO), instituts universitaires/de recherche), pays (Japon, Chine, Corée du Sud, Inde, Australie, Singapour, Thaïlande, Malaisie, Indonésie, Philippines, reste de l'Asie-Pacifique) Tendances et prévisions de l'industrie jusqu'en 2028
Analyse et perspectives du marché : Marché des vecteurs lentiviraux en Asie-Pacifique
Le marché des vecteurs lentiviraux devrait connaître une croissance du marché au cours de la période de prévision de 2021 à 2028. Data Bridge Market Research analyse que le marché croît avec un TCAC de 16,1% au cours de la période de prévision de 2021 à 2028 et devrait atteindre 207,37 millions USD d'ici 2028. La demande croissante de vecteurs lentiviraux et l'augmentation des maladies infectieuses sont les principaux moteurs qui ont propulsé la demande du marché au cours de la période de prévision.
Les vecteurs lentiviraux (LV) sont des véhicules efficaces pour le transfert de gènes dans les cellules de mammifères en raison de leur capacité à exprimer de manière stable un gène d'intérêt dans les cellules en division et non en division. Les lentivirus sont des agents pathogènes humains et animaux connus pour avoir de longues périodes d'incubation et une infection persistante. Le temps entre l'infection initiale et l'apparition des premiers symptômes peut atteindre plusieurs mois ou années.
Les biologistes moléculaires ont souvent recours à des vecteurs viraux pour introduire du matériel génétique dans les cellules. Cette procédure peut être réalisée in vivo (à l'intérieur d'un organisme vivant) ou en culture cellulaire (in vitro). Les virus ont développé des mécanismes moléculaires spécialisés pour transporter efficacement leur génome à l'intérieur des cellules qu'ils infectent.
La croissance de la population gériatrique et la demande de développement de vaccins pendant cette émergence de Covid-19 contribuent efficacement à la croissance du marché des vecteurs lentiviraux. Cependant, le manque d'évolutivité et les limites de la purification en aval des vecteurs lentiviraux peuvent entraver la croissance future d'un marché des vecteurs lentiviraux. Les initiatives stratégiques des principaux acteurs du marché et l'augmentation du financement de la génomique constituent une opportunité pour la croissance du marché des vecteurs lentiviraux en Asie-Pacifique. Les politiques réglementaires strictes et les effets secondaires associés aux produits à base de vecteurs lentiviraux constituent un défi pour la croissance future du marché.
Le rapport sur le marché des vecteurs lentiviraux fournit des détails sur la part de marché, les nouveaux développements et l'analyse du pipeline de produits, l'impact des acteurs du marché national et localisé, analyse les opportunités en termes de poches de revenus émergentes, de changements dans la réglementation du marché, d'approbations de produits, de décisions stratégiques, de lancements de produits, d'expansions géographiques et d'innovations technologiques sur le marché. Pour comprendre l'analyse et le scénario du marché, contactez-nous pour un briefing d'analyste, notre équipe vous aidera à créer une solution d'impact sur les revenus pour atteindre votre objectif souhaité.
Portée et taille du marché des vecteurs lentiviraux en Asie-Pacifique
Le marché des vecteurs lentiviraux est segmenté en huit segments notables qui sont basés sur le composant, le type, la génération, le flux de travail, la méthode de distribution, l'indication de la maladie, l'application et l'utilisateur final. La croissance entre les segments vous aide à analyser les niches de croissance et les stratégies pour aborder le marché et déterminer vos principaux domaines d'application et la différence entre vos marchés cibles.
- Sur la base des composants, le marché des vecteurs lentiviraux est segmenté en promoteurs lentiviraux, étiquettes de fusion lentivirales, systèmes d'emballage de lentivirus et autres. En 2021, le segment des systèmes d'emballage de lentivirus devrait dominer le marché des vecteurs lentiviraux en raison des avancées croissantes de la recherche en Chine, au Japon et dans d'autres pays de la région Asie-Pacifique.
- Sur la base du type, le marché des vecteurs lentiviraux est segmenté en produits et services. En 2021, le segment des produits devrait dominer le marché des vecteurs lentiviraux en raison de la forte population gériatrique.
- Sur la base de la génération, le marché des vecteurs lentiviraux est segmenté en 4e génération, 3e génération, 2e génération et 1re génération. En 2021, le segment de la 4e génération devrait dominer le marché des vecteurs lentiviraux en raison de ses effets secondaires moins importants associés aux applications de thérapie génique.
- Sur la base du flux de travail, le marché des vecteurs lentiviraux est segmenté en traitement en amont et en traitement en aval. En 2021, le segment du traitement en amont devrait dominer le marché des vecteurs lentiviraux en raison de l'augmentation du nombre de travailleurs qualifiés dans les instituts de recherche et les sociétés pharmaceutiques.
- En fonction de la méthode d'administration, le marché des vecteurs lentiviraux est segmenté en in vivo et ex vivo. En 2021, le segment in vivo devrait dominer le marché des vecteurs lentiviraux en raison du développement croissant des essais cliniques sur les vecteurs viraux.
- Sur la base de l'indication de la maladie, le marché des vecteurs lentiviraux est segmenté en cancer, troubles génétiques, maladies infectieuses, maladies vétérinaires et autres. En 2021, le segment du cancer devrait dominer le marché des vecteurs lentiviraux en raison de la forte population et de la prévalence des cas de cancer.
- En fonction des applications, le marché des vecteurs lentiviraux est segmenté en thérapie génique et vaccinologie. En 2021, le segment de la thérapie génique devrait dominer le marché des vecteurs lentiviraux en raison du tourisme médical largement répandu dans les pays asiatiques.
- On the basis of end user, the lentiviral vector market is segmented into biotechnology companies, pharmaceutical companies, contract research organizations, contract development and manufacturing organization (CDMO) and academic/ research institutes. In 2021, academic/ research institutes segment is expected to dominate the lentiviral vector market due to rising government fund for research and development procedures.
Lentiviral Vector Market Country Level Analysis
The lentiviral vector market is analysed and market size information is provided by the country, component, type, generation, workflow, delivery method, disease indication, application and end user as referenced above.
The countries covered in the lentiviral vector market report in this region are China, Japan, Australia, India, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific.
Products segment is dominating in China which is leading in the Asia-Pacific region due to high geriatric population and high vaccine production.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Strategic Initiatives by Manufactures is Creating New Opportunities for Players in the Lentiviral Vector Market
Lentiviral vector market also provides you with detailed market analysis for every country growth. Moreover, it provides detail data regarding growth in lentiviral vector sales, partnership, acquisition, distribution agreement among the market players of Asia-Pacific region. The data is available for historic period 2010 to 2019.
Competitive Landscape and Lentiviral Vector Market Share Analysis
Lentiviral vector market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to lentiviral vector market.
Les principales entreprises qui commercialisent le vecteur lentiviral sont Merck KGaA, FinVector Oy, Oxford Biomedica, Sirion-Biotech GmbH, Thermo Fisher Scientific Inc., Applied Biological Materials Inc., Creative Biolabs, Batavia Biosciences BV, Waisman Biomanufacturing, Cytiva (une filiale de Danaher), bluebird bio, Inc., System Biosciences, LLC, COBRA BIOLOGICS, Takara Bio Inc., OriGene Technologies, Inc., Sino Biological, Inc., Cell Biolabs, Inc., Lonza, GENEMEDI et FUJIFILM Diosynth Biotechnologies (une filiale de FUJIFILM Holdings Corporation), entre autres acteurs nationaux. Les analystes de DBMR comprennent les atouts concurrentiels et fournissent une analyse concurrentielle pour chaque concurrent séparément.
De nombreux contrats et accords sont également initiés par des entreprises du monde entier qui accélèrent également le marché des vecteurs lentiviraux.
Par exemple,
- En février 2021, Thermo Fisher Scientific Inc. a annoncé avoir remporté six prix lors des CMO Leadership Awards annuels. Les prix décernés par Life Science Leader et Outsourced Pharma récompensent les meilleurs partenaires de fabrication sous contrat évalués par les sociétés biopharmaceutiques et biotechnologiques. On estime que cette reconnaissance devrait renforcer sa présence à l'échelle mondiale et entraîner une augmentation de sa croissance dans les années à venir.
La collaboration, le lancement de produits, l'expansion commerciale, les récompenses et la reconnaissance, les coentreprises et d'autres stratégies des acteurs du marché renforcent l'empreinte de l'entreprise sur le marché des vecteurs lentiviraux, ce qui présente également l'avantage de favoriser la croissance des bénéfices de l'organisation.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC LENTIVIRAL VECTOR MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 COMPONENT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET APPLICATION COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 ADHERENT AND SUSPENSION CULTURES: OVERVIEW
4.2 PRICING OF LENTIVIRAL VECTORS: PRODUCT AND SERVICE
4.2.1 PRODUCT
4.2.2 SERVICES
5 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: REGULATORY FRAMEWORK
5.1 REGULATION IN THE UNITED STATES
5.2 REGULATIONS IN EUROPE
5.3 REGULATIONS IN INDIA
5.4 REGULATIONS IN JAPAN
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISE IN DEMAND FOR VIRAL VECTORS
6.1.2 EMERGENCE OF COVID-19 AND DEMAND FOR VACCINE DEVELOPMENT
6.1.3 BENEFITS OF VIRAL VECTORS FOR GENE THERAPY
6.1.4 RISE IN NUMBER OF INFECTIOUS DISEASES
6.1.5 GROWING GERIATRIC POPULATION
6.2 RESTRAINTS
6.2.1 LACK OF SCALABILITY
6.2.2 LIMITATIONS OF DOWNSTREAM PURIFICATION
6.2.3 SHORTAGE OF SKILLED PERSONNELS
6.3 OPPORTUNITIES
6.3.1 INCREASED HEALTHCARE FACILITY AND FUNDING FOR GENOMICS
6.3.2 RISE IN TECHNOLOGICAL ADVANCEMENT
6.3.3 INCREASE IN DEMAND FOR PERSONALIZED MEDICINES
6.3.4 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS
6.4 CHALLENGES
6.4.1 STRINGENT GOVERNMENT APPROVAL POLICIES
6.4.2 SIDE-EFFECTS ASSOCIATED WITH LENTIVIRAL VECTORS INTEGRATION
7 IMPACT OF COVID-19 ON THE ASIA-PACIFIC LENTIVIRAL VECTOR MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY CHAIN
7.4 STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS
7.5 CONCLUSION
8 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY COMPONENT
8.1 OVERVIEW
8.2 LENTIVIRUS PACKAGING SYSTEMS
8.3 LENTIVIRAL PROMOTER
8.3.1 LENTIVIRUS PROMOTER VECTORS
8.3.2 LENTIVIRUS PROMOTERLESS VECTORS
8.4 LENTIVIRAL FUSION TAGS
8.5 OTHERS
9 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY TYPE
9.1 OVERVIEW
9.2 PRODUCT
9.2.1 HUMAN IMMUNODEFICIENCY VIRUS (HIV)
9.2.2 FELINE IMMUNODEFICIENCY VIRUS (FIV)
9.2.3 EQUINE INFECTIOUS ANEMIA VIRUS (EIAV)
9.3 SERVICES
10 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY GENERATION
10.1 OVERVIEW
10.2 4TH GENERATION
10.3 3RD GENERATION
10.4 2ND GENERATION
10.5 1ST GENERATION
11 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY WORKFLOW
11.1 OVERVIEW
11.2 UPSTREAM PROCESSING
11.2.1 VECTOR AMPLIFICATION & EXPANSION
11.2.2 VECTOR RECOVERY/ HARVESTING
11.3 DOWNSTREAM PROCESSING
11.3.1 PURIFICATION
11.3.2 FILL-FINISH
12 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD
12.1 OVERVIEW
12.2 IN-VIVO
12.3 EX-VIVO
13 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION
13.1 OVERVIEW
13.2 CANCER
13.3 GENETIC DISORDERS
13.3.1 B-THALESSEMIA
13.3.2 X-LINKED ADRENO LEUKODYSTROPHY
13.3.3 METACHROMATIC LEUKODYSTROPHY
13.3.4 WISKOTT-ALDRICH SYNDROME
13.3.5 OTHERS
13.4 INFECTIOUS DISEASES
13.4.1 HIV
13.4.2 OTHERS
13.5 VETERINARY DISEASES
13.6 OTHERS
14 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY APPLICATION
14.1 OVERVIEW
14.2 GENE THERAPY
14.2.1 RECOMBINANT PROTEIN EXPRESSION
14.2.2 FUNCTIONAL ASSAYS
14.2.3 IN VITRO TRANSCRIPTION
14.2.4 PROTEIN CHARACTERIZATION
14.2.5 OTHERS
14.3 VACCINOLOGY
15 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY END USER
15.1 OVERVIEW
15.2 ACADEMIC/ RESEARCH INSTITUTES
15.3 PHARMACEUTICAL COMPANIES
15.4 CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS
15.5 BIOTECHNOLOGY COMPANIES
15.6 CONTRACT RESEARCH ORGANIZATIONS
16 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY REGION
16.1 ASIA-PACIFIC
16.1.1 CHINA
16.1.2 JAPAN
16.1.3 AUSTRALIA
16.1.4 INDIA
16.1.5 SOUTH KOREA
16.1.6 SINGAPORE
16.1.7 MALAYSIA
16.1.8 THAILAND
16.1.9 INDONESIA
16.1.10 PHILIPPINES
16.1.11 REST OF ASIA-PACIFIC
17 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
18 SWOT
19 COMPANY PROFILE
19.1 OXFORD BIOMEDICA
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 THERMO FISHER SCIENTIFIC INC.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 MERCK KGAA
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 LONZA
19.4.1 COMPANY SNAPSHOT
19.4.2 RECENT ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 CYTIVA (A SUBSIDIARY OF DANAHER)
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 PRODUCT PORTFOLIO
19.5.4 RECENT DEVELOPMENT
19.6 APPLIED BIOLOGICAL MATERIALS INC.
19.6.1 COMPANY SNAPSHOT
19.6.2 PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENT
19.7 BATAVIA BIOSCIENCES B.V.
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENT
19.8 BLUEBIRD BIO, INC.
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 CELL BIOLABS, INC.
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENT
19.1 CREATIVE BIOLABS
19.10.1 COMPANY SNAPSHOT
19.10.2 SERVICE PORTFOLIO
19.10.3 RECENT DEVELOPMENT
19.11 COBRA BIOLOGICS LIMITED
19.11.1 COMPANY SNAPSHOT
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENTS
19.12 FINVECTOR OY
19.12.1 COMPANY SNAPSHOT
19.12.2 SERVICE PORTFOLIO
19.12.3 RECENT DEVELOPMENT
19.13 FUJIFIM DIOSYNTH BIOTECHNOLOGIES (A SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION)
19.13.1 COMPANY SNAPSHOT
19.13.2 RECENT ANALYSIS
19.13.3 SERVICE PORTFOLIO
19.13.4 RECENT DEVELOPMENTS
19.14 GENEMEDI
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 ORIGENE TECHNOLOGIES, INC.
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENTS
19.16 SINO BIOLOGICAL, INC.
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
19.17 SIRION-BIOTECH GMBH
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENTS
19.18 SYSTEM BIOSCIENCES, LLC
19.18.1 COMPANY SNAPSHOT
19.18.2 PRODUCT PORTFOLIO
19.18.3 RECENT DEVELOPMENTS
19.19 TAKARA BIO INC.
19.19.1 COMPANY SNAPSHOT
19.19.2 RECENT ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENTS
19.2 WAISMAN BIOMANUFACTURING
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
Liste des tableaux
TABLE 1 THERMO FISHER SCIENTIFIC
TABLE 2 THE REGENTS OF THE UNIVERSITY OF MICHIGAN
TABLE 3 KERAFAST
TABLE 4 APPLIED BIOLOGICAL MATERIALS INC.
TABLE 5 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 6 ASIA-PACIFIC LENTIVIRUS PACKAGING SYSTEMS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 ASIA-PACIFIC LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 ASIA-PACIFIC LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 9 ASIA-PACIFIC LENTIVIRAL FUSION TAGS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 ASIA-PACIFIC OTHERS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 12 ASIA-PACIFIC PRODUCT IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 ASIA-PACIFIC PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 ASIA-PACIFIC SERVICES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 16 ASIA-PACIFIC 4TH-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 ASIA-PACIFIC 3RD-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 ASIA-PACIFIC 2ND-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 ASIA-PACIFIC 1ST-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY WORK FLOW, 2019-2028 (USD MILLION)
TABLE 21 ASIA-PACIFIC UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 ASIA-PACIFIC UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 23 ASIA-PACIFIC DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 ASIA-PACIFIC DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 25 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 26 ASIA-PACIFIC IN-VIVO IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 ASIA-PACIFIC EX-VIVO IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 29 ASIA-PACIFIC CANCER IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 ASIA-PACIFIC GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 ASIA-PACIFIC GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 32 ASIA-PACIFIC INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 ASIA-PACIFIC INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 34 ASIA-PACIFIC VETERINARY DISEASES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 ASIA-PACIFIC OTHERS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 37 ASIA-PACIFIC GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 ASIA-PACIFIC GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 39 ASIA-PACIFIC VACCINOLOGY IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 41 ASIA-PACIFIC ACADEMIC/ RESEARCH INSTITUTES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 ASIA-PACIFIC PHARMACEUTICAL COMPANIES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 43 ASIA-PACIFIC CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 ASIA-PACIFIC BIOTECHNOLOGY COMPANIES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 ASIA-PACIFIC CONTRACT RESEARCH ORGANIZATIONS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 47 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 48 ASIA-PACIFIC LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 49 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 50 ASIA-PACIFIC PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 51 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 52 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 53 ASIA-PACIFIC UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 54 ASIA-PACIFIC DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 55 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 56 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 57 ASIA-PACIFIC GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 58 ASIA-PACIFIC INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 59 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 60 ASIA-PACIFIC GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 61 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 62 CHINA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 63 CHINA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 64 CHINA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 CHINA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 CHINA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 67 CHINA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 68 CHINA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 69 CHINA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 70 CHINA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 71 CHINA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 72 CHINA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 73 CHINA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 74 CHINA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 75 CHINA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 76 CHINA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 77 JAPAN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 78 JAPAN LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 79 JAPAN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 80 JAPAN PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 81 JAPAN LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 82 JAPAN LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 83 JAPAN UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 84 JAPAN DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 85 JAPAN LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 86 JAPAN LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 87 JAPAN GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 88 JAPAN INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 89 JAPAN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 90 JAPAN GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 91 JAPAN LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 92 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 93 AUSTRALIA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 94 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 95 AUSTRALIA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 96 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 97 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 98 AUSTRALIA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 99 AUSTRALIA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 100 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 101 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 102 AUSTRALIA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 103 AUSTRALIA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 104 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 105 AUSTRALIA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 106 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 107 INDIA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 108 INDIA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 109 INDIA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 110 INDIA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 111 INDIA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 112 INDIA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 113 INDIA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 114 INDIA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 115 INDIA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 116 INDIA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 117 INDIA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 118 INDIA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 119 INDIA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 120 INDIA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 121 INDIA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 122 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 123 SOUTH KOREA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 124 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 125 SOUTH KOREA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 126 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 127 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 128 SOUTH KOREA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 129 SOUTH KOREA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 130 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 131 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 132 SOUTH KOREA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 133 SOUTH KOREA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 134 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 135 SOUTH KOREA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 136 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 137 SINGAPORE LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 138 SINGAPORE LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 139 SINGAPORE LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 140 SINGAPORE PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 141 SINGAPORE LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 142 SINGAPORE LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 143 SINGAPORE UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 144 SINGAPORE DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 145 SINGAPORE LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 146 SINGAPORE LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 147 SINGAPORE GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 148 SINGAPORE INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 149 SINGAPORE LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 150 SINGAPORE GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 151 SINGAPORE LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 152 MALAYSIA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 153 MALAYSIA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 154 MALAYSIA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 155 MALAYSIA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 156 MALAYSIA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 157 MALAYSIA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 158 MALAYSIA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 159 MALAYSIA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 160 MALAYSIA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 161 MALAYSIA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 162 MALAYSIA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 163 MALAYSIA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 164 MALAYSIA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 165 MALAYSIA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 166 MALAYSIA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 167 THAILAND LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 168 THAILAND LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 169 THAILAND LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 170 THAILAND PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 171 THAILAND LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 172 THAILAND LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 173 THAILAND UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 174 THAILAND DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 175 THAILAND LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 176 THAILAND LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 177 THAILAND GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 178 THAILAND INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 179 THAILAND LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 180 THAILAND GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 181 THAILAND LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 182 INDONESIA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 183 INDONESIA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 184 INDONESIA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 185 INDONESIA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 186 INDONESIA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 187 INDONESIA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 188 INDONESIA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 189 INDONESIA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 190 INDONESIA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 191 INDONESIA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 192 INDONESIA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 193 INDONESIA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 194 INDONESIA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 195 INDONESIA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 196 INDONESIA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 197 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 198 PHILIPPINES LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 199 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 200 PHILIPPINES PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 201 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 202 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 203 PHILIPPINES UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 204 PHILIPPINES DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 205 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 206 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 207 PHILIPPINES GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 208 PHILIPPINES INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 209 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 210 PHILIPPINES GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 211 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 212 REST OF ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
Liste des figures
FIGURE 1 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 11 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: SEGMENTATION
FIGURE 12 GROWING GERIATRIC POPULATION IS EXPECTED TO DRIVE THE ASIA-PACIFIC LENTIVIRAL VECTOR MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 LENTIVIRUS PACKAGING SYSTEMS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC LENTIVIRAL VECTOR MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA-PACIFIC LENTIVIRAL VECTOR MARKET
FIGURE 15 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COMPONENT, 2020
FIGURE 16 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COMPONENT, 2019-2028 (USD MILLION)
FIGURE 17 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COMPONENT, CAGR (2021-2028)
FIGURE 18 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COMPONENT, LIFELINE CURVE
FIGURE 19 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY TYPE, 2020
FIGURE 20 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY TYPE, 2019-2028 (USD MILLION)
FIGURE 21 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 22 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY GENERATION, 2020
FIGURE 24 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY GENERATION, 2019-2028 (USD MILLION)
FIGURE 25 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY GENERATION, CAGR (2021-2028)
FIGURE 26 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY GENERATION, LIFELINE CURVE
FIGURE 27 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY WORK FLOW, 2020
FIGURE 28 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY WORK FLOW, 2019-2028 (USD MILLION)
FIGURE 29 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY WORK FLOW, CAGR (2021-2028)
FIGURE 30 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY WORK FLOW, LIFELINE CURVE
FIGURE 31 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DELIVERY METHOD, 2020
FIGURE 32 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DELIVERY METHOD, 2019-2028 (USD MILLION)
FIGURE 33 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DELIVERY METHOD, CAGR (2021-2028)
FIGURE 34 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DELIVERY METHOD, LIFELINE CURVE
FIGURE 35 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DISEASE INDICATION, 2020
FIGURE 36 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DISEASE INDICATION, 2019-2028 (USD MILLION)
FIGURE 37 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DISEASE INDICATION, CAGR (2021-2028)
FIGURE 38 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DISEASE INDICATION, LIFELINE CURVE
FIGURE 39 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY APPLICATION, 2020
FIGURE 40 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY APPLICATION, 2019-2028 (USD MILLION)
FIGURE 41 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 42 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 43 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY END USER, 2020
FIGURE 44 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY END USER, 2019-2028 (USD MILLION)
FIGURE 45 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY END USER, CAGR (2021-2028)
FIGURE 46 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY END USER, LIFELINE CURVE
FIGURE 47 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: SNAPSHOT (2020)
FIGURE 48 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COUNTRY (2020)
FIGURE 49 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COUNTRY (2021 & 2028)
FIGURE 50 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COUNTRY (2020 & 2028)
FIGURE 51 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COMPONENT (2021-2028)
FIGURE 52 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: COMPANY SHARE 2020 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
